Teilah Huth: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(chronology; hyperlinks) |
(converted ref) |
||
Line 1: | Line 1: | ||
[[File:Teilah Huth.png|200px|thumb|right|Source:Griffith Health Institute]] | [[File:Teilah Huth.png|200px|thumb|right|Source:Griffith Health Institute]] | ||
'''Teilah Kathryn Huth''', PhD, is a researcher at the [[National Centre for Neuroimmunology and Emerging Diseases]] (NCNED) at Griffith University, Australia. Her primary interest is in investigating the role of Natural Killer (NK) cells in ME/CFS and why the function of NK cells has been found to be reduced in patients with ME/CFS. <ref>https://www.griffith.edu.au/__data/assets/pdf_file/0007/686599/NCNED-Newsletter-February-2015.pdf</ref> | '''Teilah Kathryn Huth''', PhD, is a researcher at the [[National Centre for Neuroimmunology and Emerging Diseases]] (NCNED) at Griffith University, Australia. Her primary interest is in investigating the role of Natural Killer (NK) cells in ME/CFS and why the function of NK cells has been found to be reduced in patients with ME/CFS.<ref>https://www.griffith.edu.au/__data/assets/pdf_file/0007/686599/NCNED-Newsletter-February-2015.pdf</ref> | ||
==Doctorate thesis== | ==Doctorate thesis== | ||
Line 6: | Line 6: | ||
==Notable studies== | ==Notable studies== | ||
*2013, Measurement of [[natural killer cell]] apoptotic inducing lytic proteins in peripheral blood mononuclear cells and isolated [[natural killer cell]]s<ref> Huth | *2013, Measurement of [[natural killer cell]] apoptotic inducing lytic proteins in peripheral blood mononuclear cells and isolated [[natural killer cell]]s<ref>{{Cite journal|last=Teilah|first=Huth|author-link=Teilah Huth|last2=Brenu|first2=Ekua|author-link2=Ekua Brenu|last3=Kevin|first3=Ashton|author-link3=|last4=Staines|first4=Don|author-link4=Donald Staines|last5=Gradisnik|first5=Sonya|author-link5=Sonya Marshall-Gradisnik|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=2013|title=Measurement of natural killer cell apoptotic inducing lytic proteins in peripheral blood mononuclear cells and isolated natural killer cells.|url=http://www.frontiersin.org/10.3389/conf.fimmu.2013.02.00940/event_abstract|journal=Frontiers in Immunology|volume=4|issue=|pages=|doi=10.3389/conf.fimmu.2013.02.00940|issn=1664-3224|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [https://www.frontiersin.org/10.3389/conf.fimmu.2013.02.00940/event_abstract (Abstract)] | ||
*2013, The role of Dendritic Cells and Monocytes in | *2013, The role of Dendritic Cells and Monocytes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis<ref>{{Cite journal|last=Brenu|first=Ekua|author-link=Ekua Brenu|last2=Huth|first2=Teilah|author-link2=Teilah Huth|last3=Hardcastle|first3=Sharni|author-link3=Sharni Hardcastle|last4=Cosgrave|first4=Liam|author-link4=|last5=Staines|first5=Don|author-link5=Donald Staines|last6=Marshall-Gradisnik|first6=Sonya|author-link6=Sonya Marshall-Gradisnik|last7=|first7=|last8=|first8=|date=2013|title=The role of Dendritic Cells and Monocytes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|url=http://www.frontiersin.org/10.3389/conf.fimmu.2013.02.01010/event_abstract|journal=Frontiers in Immunology|volume=4|issue=|pages=|doi=10.3389/conf.fimmu.2013.02.01010|issn=1664-3224|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [https://www.frontiersin.org/10.3389/conf.fimmu.2013.02.01010/event_abstract (Abstract)] | ||
*2014, The Role of Adaptive and Innate Immune Cells in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref name="BrenuEW2014"/> | *2014, The Role of Adaptive and Innate Immune Cells in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref name="BrenuEW2014" /> - [https://www.researchgate.net/publication/259350347_The_Role_of_Adaptive_and_Innate_Immune_Cells_in_Chronic_Fatigue_Syndrome_Myalgic_Encephalomyelitis (Full Text)] | ||
*2014, Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] (CFS/ME)<ref name="Hardcastle, 2014"/> | *2014, Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] (CFS/ME)<ref name="Hardcastle, 2014" /> - [https://www.omicsonline.org/open-access/analysis-relationship-immune-dysfunction-symptom-severity-patients-chronic-fatigue-2155-9899.1000190.php?aid=22894 (Full Text)] | ||
*2014, Characterization of [[Natural killer cell|Natural Killer Cell]] Phenotypes in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref name="Huth, 2014"/> [https://www.omicsonline.org/open-access/characterization-of-natural-killer-cell-phenotypes-in-chronic-fatigue-syndrome-2155-9899.1000223.pdf (Full Text)] | *2014, Characterization of [[Natural killer cell|Natural Killer Cell]] Phenotypes in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]]<ref name="Huth, 2014" /> - [https://www.omicsonline.org/open-access/characterization-of-natural-killer-cell-phenotypes-in-chronic-fatigue-syndrome-2155-9899.1000223.pdf (Full Text)] | ||
*2015, Characterisation of cell functions and receptors in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] (CFS/ME)<ref name="Hardcastle, 2015"/> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450981/ (Full Text)] | *2015, Characterisation of cell functions and receptors in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] (CFS/ME)<ref name="Hardcastle, 2015" /> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450981/ (Full Text)] | ||
*2015, Longitudinal analysis of immune abnormalities in varying severities of [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] patients<ref name="Hardcastle, 092015"/> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568602/ (Full Text)] | *2015, Longitudinal analysis of immune abnormalities in varying severities of [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] patients<ref name="Hardcastle, 092015" /> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568602/ (Full Text)] | ||
*2015, Serum Immune Proteins in Moderate and Severe [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] Patients<ref name="Hardcastle, 09052015"/> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615236/ (Full Text)] | *2015, Serum Immune Proteins in Moderate and Severe [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] Patients<ref name="Hardcastle, 09052015" /> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615236/ (Full Text)] | ||
*2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− [[natural killer cell]]s in | *2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− [[natural killer cell]]s in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients<ref name="Huth, 2016" /> - [http://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0859-z (Full Text)] | ||
*2016, Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of [[Natural killer cell|Natural Killer Cells]] from an Australian Population of | *2016, Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of [[Natural killer cell|Natural Killer Cells]] from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients<ref name="Huth,TK, 2016" /> -[https://www.ncbi.nlm.nih.gov/pubmed/27346947 (Full Text)] | ||
*2016, [[Natural killer cell]]s and single nucleotide polymorphisms of specific ion channels and receptor genes in [[ME/CFS|myalgic encephalomyelitis/chronic fatigue syndrome]]<ref name="Marshall-Gradisnik,SM 2016"/> | *2016, [[Natural killer cell]]s and single nucleotide polymorphisms of specific ion channels and receptor genes in [[ME/CFS|myalgic encephalomyelitis/chronic fatigue syndrome]]<ref name="Marshall-Gradisnik,SM 2016" /> - [https://www.dovepress.com/natural-killer-cells-and-single-nucleotide-polymorphisms-of-specific-i-peer-reviewed-fulltext-article-TACG (Full Text)] | ||
*2016, Pilot Study of [[Natural killer cell|Natural Killer Cells]] in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] and [[Multiple sclerosis|Multiple Sclerosis]]<ref name="HuthTK2016"/> | *2016, Pilot Study of [[Natural killer cell|Natural Killer Cells]] in [[ME/CFS|Chronic Fatigue Syndrome/Myalgic Encephalomyelitis]] and [[Multiple sclerosis|Multiple Sclerosis]]<ref name="HuthTK2016" /> - [https://www.ncbi.nlm.nih.gov/pubmed/26381393 (Abstract)] | ||
==Talks and interviews== | ==Talks and interviews== | ||
Line 44: | Line 44: | ||
| pmid = 24343819 | doi = 10.1093/intimm/dxt068 | | pmid = 24343819 | doi = 10.1093/intimm/dxt068 | ||
}}</ref> | }}</ref> | ||
<ref name="Hardcastle, 2014"> | <ref name="Hardcastle, 2014">{{Citation | ||
{{Citation | |||
| last1 = Hardcastle | first1 = Sharni L. | authorlink1 = Sharni Hardcastle | | last1 = Hardcastle | first1 = Sharni L. | authorlink1 = Sharni Hardcastle | ||
| last2 = Brenu | first2 = Ekua W. | authorlink2 = Ekua Brenu | | last2 = Brenu | first2 = Ekua W. | authorlink2 = Ekua Brenu | ||
Line 63: | Line 62: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Hardcastle, 2015"> | <ref name="Hardcastle, 2015">{{Citation | ||
{{Citation | |||
| last1 = Hardcastle | first1 = SL | authorlink1 = Sharni Hardcastle | | last1 = Hardcastle | first1 = SL | authorlink1 = Sharni Hardcastle | ||
| last2 = Brenu | first2 = EW | authorlink2 = Ekua Brenu | | last2 = Brenu | first2 = EW | authorlink2 = Ekua Brenu | ||
Line 80: | Line 78: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Hardcastle, 092015"> | <ref name="Hardcastle, 092015">{{Citation | ||
{{Citation | |||
| last1 = Hardcastle | first1 = Sharni Lee | authorlink1 = Sharni Hardcastle | | last1 = Hardcastle | first1 = Sharni Lee | authorlink1 = Sharni Hardcastle | ||
| last2 = Brenu | first2 = Ekua Weba | authorlink2 = Ekua Brenu | | last2 = Brenu | first2 = Ekua Weba | authorlink2 = Ekua Brenu | ||
Line 96: | Line 93: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Hardcastle, 09052015"> | <ref name="Hardcastle, 09052015">{{Citation | ||
{{Citation | |||
| last1 = Hardcastle | first1 = SL | authorlink1 = Sharni Hardcastle | | last1 = Hardcastle | first1 = SL | authorlink1 = Sharni Hardcastle | ||
| last2 = Brenu | first2 = EW | authorlink2 = Ekua Brenu | | last2 = Brenu | first2 = EW | authorlink2 = Ekua Brenu | ||
Line 113: | Line 109: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Huth, 2014"> | <ref name="Huth, 2014">{{Citation | ||
{{Citation | |||
| last1 = Huth | first1 = Teilah K. | authorlink1 = Teilah Huth | | last1 = Huth | first1 = Teilah K. | authorlink1 = Teilah Huth | ||
| last2 = Brenu | first2 = Ekua | authorlink2 = Ekua Brenu | | last2 = Brenu | first2 = Ekua | authorlink2 = Ekua Brenu | ||
Line 130: | Line 125: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Huth, 2016"> | <ref name="Huth, 2016">{{Citation | ||
{{Citation | |||
| last1 = Huth | first1 = Teilah K. | authorlink1 = Teilah Huth | | last1 = Huth | first1 = Teilah K. | authorlink1 = Teilah Huth | ||
| last2 = Staines | first2 = Donald | authorlink2 = Donald Staines | | last2 = Staines | first2 = Donald | authorlink2 = Donald Staines | ||
Line 142: | Line 136: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Huth,TK, 2016"> | <ref name="Huth,TK, 2016">{{Citation | ||
{{Citation | |||
| last1 = Huth | first1 = T.K. | authorlink1 = Teilah Huth | | last1 = Huth | first1 = T.K. | authorlink1 = Teilah Huth | ||
| last2 = Brenu | first2 = E.W. | authorlink2 = Ekua Brenu | | last2 = Brenu | first2 = E.W. | authorlink2 = Ekua Brenu | ||
Line 168: | Line 161: | ||
| url = https://www.ncbi.nlm.nih.gov/pubmed/26381393 | | url = https://www.ncbi.nlm.nih.gov/pubmed/26381393 | ||
}}</ref> | }}</ref> | ||
<ref name="Marshall-Gradisnik,SM 2016"> | <ref name="Marshall-Gradisnik,SM 2016">{{Citation | ||
{{Citation | |||
| last1 = Marshall-Gradisnik | first1 = Sonya M. | authorlink1 = Sonya Marshall-Gradisnik | | last1 = Marshall-Gradisnik | first1 = Sonya M. | authorlink1 = Sonya Marshall-Gradisnik | ||
| last2 = Huth | first2 = Teilah | authorlink2 = Teilah Huth | | last2 = Huth | first2 = Teilah | authorlink2 = Teilah Huth |
Revision as of 16:38, November 14, 2019
Teilah Kathryn Huth, PhD, is a researcher at the National Centre for Neuroimmunology and Emerging Diseases (NCNED) at Griffith University, Australia. Her primary interest is in investigating the role of Natural Killer (NK) cells in ME/CFS and why the function of NK cells has been found to be reduced in patients with ME/CFS.[1]
Doctorate thesis[edit | edit source]
- 2016, Investigation of Cellular and Genetic Mechanisms Required for Natural Killer Cell Cytotoxic Activity in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[2] (Thesis Full Text)
Notable studies[edit | edit source]
- 2013, Measurement of natural killer cell apoptotic inducing lytic proteins in peripheral blood mononuclear cells and isolated natural killer cells[3] - (Abstract)
- 2013, The role of Dendritic Cells and Monocytes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[4] - (Abstract)
- 2014, The Role of Adaptive and Innate Immune Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[5] - (Full Text)
- 2014, Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)[6] - (Full Text)
- 2014, Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[7] - (Full Text)
- 2015, Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)[8] - (Full Text)
- 2015, Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[9] - (Full Text)
- 2015, Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[10] - (Full Text)
- 2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[11] - (Full Text)
- 2016, Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[12] -(Full Text)
- 2016, Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome[13] - (Full Text)
- 2016, Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis[14] - (Abstract)
Talks and interviews[edit | edit source]
Online presence[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ https://www.griffith.edu.au/__data/assets/pdf_file/0007/686599/NCNED-Newsletter-February-2015.pdf
- ↑ https://www120.secure.griffith.edu.au/rch/items/7e77e955-87f6-4adf-b923-6d62fdc64d86/1/
- ↑ Teilah, Huth; Brenu, Ekua; Kevin, Ashton; Staines, Don; Gradisnik, Sonya (2013). "Measurement of natural killer cell apoptotic inducing lytic proteins in peripheral blood mononuclear cells and isolated natural killer cells". Frontiers in Immunology. 4. doi:10.3389/conf.fimmu.2013.02.00940. ISSN 1664-3224.
- ↑ Brenu, Ekua; Huth, Teilah; Hardcastle, Sharni; Cosgrave, Liam; Staines, Don; Marshall-Gradisnik, Sonya (2013). "The role of Dendritic Cells and Monocytes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". Frontiers in Immunology. 4. doi:10.3389/conf.fimmu.2013.02.01010. ISSN 1664-3224.
- ↑ Brenu, EW; Huth, TK; Hardcastle, SL; Fuller, K; Kaur, M; Johnston, S; Ramos, S; Staines, D; Marshall-Gradisnik, S (2014), "The Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis", International Immunology, 26 (4): 233-42, doi:10.1093/intimm/dxt068, PMID 24343819
- ↑ Hardcastle, Sharni L.; Brenu, Ekua W.; Johnston, Samantha; Nguyen, Thao; Huth, Teilah K.; Kaur, Manprit; Ramos, Sandra; Salajegheh, Ali; Staines, Donald R.; Marshall-Gradisnik, Sonya (2014), "Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", Journal of Clinical & Cellular Immunology, 5 (190), doi:10.4172/2155-9899.1000190
- ↑ Huth, Teilah K.; Brenu, Ekua; Nguyen, Thao; Hardcastle, Sharni L.; Johnston, Samantha; Ramos, Sandra; Staines, Donald R.; Marshall-Gradisnik, Sonya M. (2014), "Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", Journal of Clinical & Cellular Immunology, 5 (3), doi:10.4172/2155-9899.1000223
- ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015), "Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", BMC Immunology, 16 (35), doi:10.1186/s12865-015-0101-4
- ↑ Hardcastle, Sharni Lee; Brenu, Ekua Weba; Johnston, Samantha; Nguyen, Thao; Huth, Teilah; Ramos, Sandra; Staines, Donald; Marshall-Gradisnik, Sonya (2015), "Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients", Journal of Translational Medicine, 13 (299), doi:10.1186/s12967-015-0653-3
- ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015), "Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients", International Journal of Medical Sciences, 12 (10): 764-772, doi:10.7150/ijms.12399
- ↑ Huth, Teilah K.; Staines, Donald; Marshall-Gradisnik, Sonya (2016), "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients", Journal of Translational Medicine, 14 (97), doi:10.1186/s12967-016-0859-z
- ↑ Huth, T.K.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S.M. (2016), "Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients", Gene Regulation and Systems Biology, 10: 43–49, doi:10.4137/GRSB.S39861
- ↑ Marshall-Gradisnik, Sonya M.; Huth, Teilah; Chacko, Anu; Johnston, Samantha; Smith, Peter; Staines, Donald R. (2016), "Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome", The Application of Clinical Genetics, 9: 39—47, doi:10.2147/TACG.S99405
- ↑ Huth, TK; Brenu, EW; Ramos, S; Nguyen, T; Broadley, S; Staines, D; Marshall-Gradisnik, S (January 2016), "Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis", Scand J Immunol, 83(1): 44-51, doi:10.1111/sji.12388, PMID 26381393